Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results
An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...
Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...
Fierce Biotech11d
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
pharmaphorum11d
Pfizer's new drug data in breast cancer draws muted response
Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...
BioSpace11d
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...
PMLive3d
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
Labiotech.eu2d
Breast cancer treatments heat up: Five therapies poised to transform patient outcomes
Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...
STAT11d
Diseased protein degrader shows mixed results in breast cancer trial
Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...
Yahoo Finance11d
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...
BioPharma Dive11d
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Breast Cancer Therapeutics Market Size to Reach US$ 63.9 Billion by 2030, Driven by Innovations and Growing Demand, Says The Insight Partners
The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...